VladoPerkovic University of New South Wales, Sydney, AustraliaAustralia

VladoPerkovic
Scientia Professor Vlado Perkovic is the Provost at the University of New South Wales, and previously the Dean of Medicine and Health at the University of New South Wales in Sydney, Australia, Professorial Fellow at The George Institute, Australia, and was a Staff Specialist in Nephrology at the Royal North Shore Hospital. His research focus is in clinical trials, epidemiology, in particular preventing the progression of kidney disease and its complications. He leads several international clinical trials is involved in developing Australian and global treatment guidelines. Has played a central role in the development of an affordable dialysis system, which was a Eureka Prize finalist 2017. Vlado is a member of the NHMRC Principal Committee on Research Translation, on the Board of the Australian Clinical Trials Alliance and the Association of Australian Medical Research Institutes. Chair of the ISN Advancing Clinical Trials (ISN-ACT) group; a Fellow of the Royal Australasian College of Physicians, the Australian Academy of Health and Medical Sciences. He serves on the Editorial Boards of Journal of the American Society of Nephrology, Circulation, the New England Journal of Medicine.
Institution

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10 a.m.
DebasishBanerjee Chairperson dbanerje@sgul.ac.ukSt George's University Hospital NHS Foundation TrUnited Kingdom
MegJardine Chairperson NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • Setting the Scene
    MegJardine Speaker NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • DM and CKD: Which Treatment Should I Use for Different Populations?
    KatherineTuttle Speaker University of Washington School of Medicine, Division of NephrologyUnited States
  • How to Design Studies on Answering Unanswered Questions
    VladoPerkovic Speaker vlado.perkovic@unsw.edu.auUniversity of New South Wales, Sydney, AustraliaAustralia
  • The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes
    DavidWheeler Speaker University College LondonUnited Kingdom
  • Q and A
Hall C4